AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00284271
Drug: Adramycin
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00284271
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00284271
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00284271
Drug: Bleomycin
RxNorm normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00284271
Drug: Erythropoietin beta
RxNorm normalized name: Beta Carotene
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01012960
Drug: methylnaltrexone
RxNorm normalized name: Methylnaltrexone
DrugBank: Methylnaltrexone (DB06800)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 0,15 mg/kg sc ( subcutaneously)once per volunteer
Trial: NCT00859053
Drug: BMS-790052
RxNorm normalized name: BMS-790052
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules, Oral, 30 mg, single dose, one day
Trial: NCT02056782
Drug: Dociparstat sodium
RxNorm normalized name: Dociparstat sodium
DrugBank: Dociparstat sodium (DB16481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The following induction regimen was administered:~* Cytarabine (100 mg/m2/day) via continuous intravenous (IV) infusion 24 hours daily for 7 days.~* Idarubicin (12 mg/m2/day) IV on Days 1, 2, and 3.~* Dociparstat (4 mg/kg) given over 5 minutes IV, immediately after the idarubicin dose on Day 1, followed by a continuous IV infusion (0.25 mg/kg/hr for 24 hours daily) for a total of 7 days.
Trial: NCT04161989
Drug: omega-3 fatty acids
RxNorm normalized name: Omega-3 Fatty Acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: . The Omega 3 plus capsule contains 1000 mg Fish Oil (contains Eicosapentaenoic acid 13% \& Docosahexaenoic acid 9%) plus 100 mg Wheat Germ Oil (Linoleic acid 52- 59%) as a natural source of Vitamin E.
Trial: NCT04161989
Drug: vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prontogest 400 mg vaginal suppository contains progesterone 400 mg.
Trial: NCT00869895
Drug: E7050
RxNorm normalized name: Elafibranor
DrugBank: Elafibranor (DB05187)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dosing starting at 100 mg once daily. After the MTD of once daily dosing has been determined, subsequent cohorts will be treated with a divided dosing schedule either twice or three times daily. The starting dose for this schedule will be an appropriate level below the MTD for once daily dosing.
Trial: NCT01023750
Drug: Fenofibrate
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will give a baseline blood sample and begin the 4 week course of fenofibrate. Patients will be given a 33-day dose of 145 mg of fenofibrate to be taken by mouth once a day. All doses of fenofibrate will be purchased in one batch, prepared at the pharmacy under supervision. A study nurse will collect each patient's 33-day dose of fenofibrate from the pharmacy and dispense to the study participants in the clinics. Patients will be given instructions on how to take the medication and given a 24-hr phone number to call in case of questions or need for additional care. Each patient will receive a phone call at least 2 times during the course of the trial to monitor the progress. Our co-investigators, who are also physicians will be available in case a study participant needs additional care. If not available, study participants will be able to reach the cardiologist or endocrinologist on call through an additional phone number we will provide.
Trial: NCT00963495
Drug: Clioquinol
RxNorm normalized name: Clioquinol
DrugBank: Clioquinol (DB04815)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will take Clioquniol at escalating doses depending on when they enter into the trial.
Trial: NCT04340401
Drug: SHR-1210
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 3 cycles induction CapeOX and SHR-1210
Trial: NCT00782548
Drug: KADIAN (morphine sulfate sustained-release) capsules
RxNorm normalized name: morphine sulfate Extended Release Oral Capsule [Kadian]
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsules, 30 mg
Trial: NCT00782548
Drug: Avinza (morphine sulfate sustained-release) capsules
RxNorm normalized name: morphine sulfate Extended Release Oral Capsule [Avinza]
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsules, 30 mg
Trial: NCT00191100
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00191100
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00293878
Drug: Disodium Ascorbyl Phytostanol Phosphate (FM-VP4)
RxNorm normalized name: disodium ascorbyl sitostanol phosphate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02966782
Drug: venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet
Trial: NCT02966782
Drug: azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Powder for injection, subcutaneously or intravenous
Trial: NCT01889407
Drug: Idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 mg/m2, iv drip on days 1-3
Trial: NCT04340401
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CapeOX is a combination chemotherapy regimen with OXA and CAPE, patients with high-risk rectal cancer will receive 3 cycles induction CapeOX and SHR-1210, intensity modulated radiotherapy with concurrent capecitabine and 2 cycles consolidation CapeOX and total mesorectal excision.
Trial: NCT01325415
Drug: moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg tablet
Trial: NCT02760199
Drug: 89Zr-AMG211
RxNorm normalized name: 89ZR-BEVACIZUMAB
DrugBank: Bevacizumab zirconium Zr-89 (DB14907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 89Zr-AMG211 for imaging.
Trial: NCT01506167
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab was administered as part of standard first-line treatment
Trial: NCT02643407
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60mg/m2
Trial: NCT00884312
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carfilzomib dose levels ranged from 11 to 27 mg/m² for 2- to 10-minute infusions and 36 to 56 mg/m² for 30-minute infusions. Carfilzomib doses were administered on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. Dose level reduction to a minimum dose of 11 mg/m² for toxicity was permitted.
Trial: NCT02692703
Drug: glecaprevir/pibrentasvir
RxNorm normalized name: GLECAPREVIR/PIBRENTASVIR
DrugBank: Pibrentasvir (DB13878)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet; glecaprevir coformulated with pibrentasvir
Trial: NCT00037479
Drug: ceftriaxone
RxNorm normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02643407
Drug: Nedaplatin
RxNorm normalized name: Nedaplatin
DrugBank: Nedaplatin (DB13145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80mg/m2
Trial: NCT02643407
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75mg/m2
Trial: NCT00259896
Drug: exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00751270
Drug: Valacyclovir
RxNorm normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The oral prodrug valacyclovir was given beginning 1-3 days following the AdV-tk. Valacyclovir tablets were taken three times a day for a total of 14 days.
Trial: NCT02468115
Drug: VIS410
RxNorm normalized name: IMMUNOGLOBULIN G1, ANTI-(INFLUENZA HEMAGGLUTININ) (HUMAN MONOCLONAL VIS410 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL VIS410 .KAPPA.-CHAIN, DIMER
DrugBank: VIS-410 (DB19067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single fixed IV dose of VIS410
Trial: NCT02193867
Drug: Sebelipase Alfa
RxNorm normalized name: Sebelipase alfa
DrugBank: Sebelipase alfa (DB11563)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sebelipase alfa is a recombinant human lysosomal acid lipase. The investigational medicinal product is an enzyme replacement therapy intended for treatment of participants with LAL-D. Dosing occurred once weekly for up to 3 years.
Trial: NCT02254187
Drug: Salmeterol capsule - low
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02254187
Drug: Salmeterol capsule - high
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02254187
Drug: Salmeterol via Serevent® Diskus®
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03053544
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will self-administer 500mg metformin twice daily by mouth: 1) beginning 1-2 weeks prior to standard of care CRT, 2) during standard of care CRT and 3) until 30 days after the end of standard of care CRT.
Trial: NCT03716024
Drug: Linezolid
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-mixed 600 mg IV infusion solution; Linezolid 600 mg tablets
Trial: NCT00783003
Drug: GSK233705 and GW642444
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inhaled Long acting muscarinic receptor antagonist (LAMA) and a inhaled Long acting Beta 2 agonist (LABA) both in development as treatment for Chronic Obstructive Pulmonary Disease, taken in combination.
Trial: NCT00449020
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CARBOPLATIN (AUC=2) IV in 250 cc NS over 30 minutes, weekly for seven weeks (Days #1, #8, #15, #22, #29, #36 and #43) along with radiation.
Trial: NCT00449020
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DOCETAXEL 75 mg/m2 IV over one hour every three weeks for 3 cycles.
Trial: NCT00449020
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IRINOTECAN 30 mg/m2 IV over 90 minutes weekly for seven weeks (Days #1, #8, #15, #22, #29, #36 and #43) along with radiation.
Trial: NCT00284050
Drug: Ranibizumab 0.3 mg
RxNorm normalized name: ranibizumab 0.3 MG in 0.05 ML Injection
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 6 mg/ml ranibizumab solution for intravitreal injection
Trial: NCT00284050
Drug: Ranibizumab 0.5 mg
RxNorm normalized name: ranibizumab 0.5 MG in 0.05 ML Injection
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg/ml ranibizumab solution for intravitreal injection
Trial: NCT00284050
Drug: Sham injection
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
DrugBank: Bean (DB14709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-treatment control for sham intravitreal injection.
Trial: NCT01803373
Drug: Treatment C
RxNorm normalized name: Acne Treatment Cream
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 grams (ie,20mg/g) equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
Trial: NCT03721653
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 mg/kg iv over 30 minutes day 1
Trial: NCT03721653
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 165 mg/sqm iv over 60 minutes day 1
Trial: NCT03721653
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 85 mg/sqm iv over 2 hours day 1
Trial: NCT03721653
Drug: 5-fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3200 mg/sqm 48 h-continuous infusion
Trial: NCT03721653
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 840 mg iv over 30 minutes (60 minutes at the first infusion) day 1
Trial: NCT01250730
Drug: PF-02341066
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1: a 150 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 1 x 100 mg IRT.
Trial: NCT01250730
Drug: PF-02341066
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 2: a 250 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 2 x 100 mg IRTs.
Trial: NCT01250730
Drug: PF-02341066
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 3: a 400 mg single dose of PF-02341066 administered as 4 x 100 mg IRTs.
Trial: NCT03878628
Drug: Adipose tissue-derived mesenchymal stem cells
RxNorm normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSCC_ASC(22), a ready-to-use suspension containing 22 million adipose tissue-derived mesenchymal stem cells per millilitre
Trial: NCT03097445
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mailed 5-week course of Habitrol® transdermal nicotine patches
Trial: NCT00728351
Drug: vildagliptin + metformin
RxNorm normalized name: vildagliptin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00728351
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1000 bid metformin
Trial: NCT01186458
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 25 mg/m2 IV over 30 minutes on days 1, 2, 4. Cycle = 28 days; maximum of 6 cycles of therapy.
Trial: NCT01186458
Drug: Velcade
RxNorm normalized name: Velcade
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Velcade (given after fludarabine)1.3 mg/m2 IV push over 3 to 5 seconds on days 1, 4, 8, 11. Cycle = 28 days; maximum of 6 cycles of therapy.
Trial: NCT01186458
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab given after Velcade) 375 mg/m2 IV piggyback on day 1. Cycle = 28 days; maximum of 6 cycles of therapy.
Trial: NCT01283360
Drug: Tenofovir 1% Gel
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tenofovir 1% gel will be supplied by CONRAD (Arlington, VA, USA). Under direction from CONRAD, DPT Laboratories will manufacture the tenofovir 1% gel and analyze/release the gels under cGMP. DPT Laboratories will fill the applicators designed for vaginal use with tenofovir 1% gel to create pre-filled applicators and package each applicator and plunger in a wrapper. Each pre-filled applicator will contain and deliver a dose of approximately 4 mL of tenofovir 1% gel (equal to 4.4 g).
Trial: NCT02460302
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Micronized vaginal progesterone 100mg inserted vaginally
Trial: NCT02685085
Drug: Misoprostol ( Prostaglandin E2)
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02427893
Drug: Cobimetinib
RxNorm normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A potent and highly selective inhibitor of MEK1 and MEK2, central components of the RAS/RAF pathway.
Trial: NCT02427893
Drug: Vemurafenib
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A low molecular weight, orally available inhibitor of the activated form of the BRAF serine-threonine kinase enzyme, which is commonly found in melanoma
Trial: NCT04567329
Drug: NOV03
RxNorm normalized name: NOV03
DrugBank: Perfluorohexyloctane (DB17823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% perfluorohexyloctane
Trial: NCT04567329
Drug: Saline Solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.6% sodium chloride solution
Trial: NCT04637360
Drug: Cinacalcet Tablets
RxNorm normalized name: Cinacalcet Tablets
DrugBank: Cinacalcet (DB01012)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All study subjects were treated with a fixed dose of oral Cinacalcet (25 mg/day) from baseline to 6 months.
Trial: NCT04637360
Drug: calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All hyperparathyroidism were treated as traditional therapy with oral calcitriol 0.25 mcg(dosage according to IPTH serum level) from baseline to 6 months.
Trial: NCT01728480
Drug: entolimod
RxNorm normalized name: Entolimod
DrugBank: Entolimod (DB12304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given SC
Trial: NCT01728480
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00339157
Drug: Anakinra
RxNorm normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01615185
Drug: full-dose amisulpride
DrugBank: Amisulpride (DB06288)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amisulpride 800mg/d
Trial: NCT00500201
Drug: SB- 773812 60 mg
RxNorm normalized name: SB-773812
DrugBank: SB-773812 (DB16042)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB- 773812 will be available dose strength of 60 mg and administered orally by subjects.
Trial: NCT00500201
Drug: SB- 773812 120 mg
RxNorm normalized name: SB-773812
DrugBank: SB-773812 (DB16042)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB- 773812 will be available dose strength of 120 mg and administered orally by subjects.
Trial: NCT00633672
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg Oral tablet once daily
Trial: NCT00633672
Drug: Ranitidine
RxNorm normalized name: Ranitidine
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150mg oral twice daily
Trial: NCT00633672
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg oral tablet once daily
Trial: NCT00768963
Drug: ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.5 mg subconjunctival ranibizumab 3 days prior to surgery
Trial: NCT00768963
Drug: ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.5 mg subconjunctival ranibizumab at the time of surgery
Trial: NCT00622245
Drug: Lu AA34893
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: per oral doses, divided in twice daily administrations as capsules, during 12 weeks, followed by a one-week tapering period
Trial: NCT03101358
Drug: SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One (1) Finger Tip Unit (FTU), or approximately 0.5 g, of SOR007 ointment will be applied topically to a 50 cm2 treatment area.
Trial: NCT00474058
Drug: Rotigotine
RxNorm normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rotigotine transdermal patches:~10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h)~Optimal dosing: The maximum Rotigotine dose allowed is 16mg/24h
Trial: NCT00622245
Drug: Quetiapine fumarate
RxNorm normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: per oral, once daily, during 12 weeks, followed by a one-week tapering period
Trial: NCT01445769
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib was provided as 5 mg tablets. Dose increases were only permitted at wks 12 \& 18 for lack of efficacy. Increases were restricted to patients who didn't meet criteria for a dose hold over the prior 6 wks, had a platelet count ≥ 100 x 10\^9/L at wk 12 or ≥ 150 x 10\^9/L at wk 18, and had a self-reported PGIC score of 3 (minimally improved) to 7 (very much worse) OR the subject's palpable spleen length below the costal margin was reduced by less than 40% relative to Baseline. Dose increases were elective and not required. Subjects were permitted a dose increase of 5 mg BID to 15 mg BID at wk 12 and to a maximum of 20 mg BID at wk 18. The protocol required dose decreases for thrombocytopenia (platelets \<100 x 10\^9/L) or protocol-defined anemia (decline in hemoglobin of at least 2 g/dL to a level \< 8 g/dL, development of transfusion dependence, or a 50% increase in transfusion requirements for transfusion dependent subjects).